ArticleEuropean urology2022
Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.
Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis.Investigative and clinical urology · 2024Pooled it
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.European urology · 2023Pooled it
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.The Journal of urology · 2023Guideline
- Quality of life and secondary outcomes for open versus robot-assisted radical cystectomy: a double-blinded, randomised feasibility trial.World journal of urology · 2022Trial
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.JAMA network open · 2026Article
- Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics.European urology open science · 2026Article
- Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort.BMC cancer · 2025Article
- Lifestyle-Related Factors and Dietary Components that Affect the Risk of Prostate Cancer in a Brazilian Study Group.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.PloS one · 2025Article
- Global, regional, and national prevalence of prostate cancer from 1990 to 2021: a trend and health inequality analyses.Frontiers in public health · 2025Article
- The Association ofAdvanced biomedical research · 2025Article
- Associations of specific food sources of dietary fat with prostate cancer incidence and mortality: results from a large prospective cohort.Frontiers in nutrition · 2025Article
- Review
- Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.Life (Basel, Switzerland) · 2024Review
- BioPrev-C - development and validation of a contemporary prostate cancer risk calculator.Frontiers in oncology · 2024Article
- Article
- Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.The Journal of urology · 2023Article
- Review
- The profile of Black South African men diagnosed with prostate cancer in the Free State, South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 9 institutions in 5 countries.
Funding
Abstract
backgroundThe risk of high-grade prostate cancer, given a family history of cancer, has been described in the general population, but not among men selected for prostate biopsy in an international cohort.
objectiveTo estimate the risk of high-grade prostate cancer on biopsy based on a family history of cancer. DESIGN, SETTING, AND
participantsThis is a multicenter study of men undergoing prostate biopsy from 2006 to 2019, including 12 sites in North America and Europe. All sites recorded first-degree prostate cancer family histories; four included more detailed data on the number of affected relatives, second-degree relatives with prostate cancer, and breast cancer family history. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regressions evaluated odds of high-grade (Gleason grade group ≥2) prostate cancer. Separate models were fit for family history definitions, including first- and second-degree prostate cancer and breast cancer family histories. RESULTS AND LIMITATIONS: A first-degree prostate cancer family history was available for 15 799 men, with a more detailed family history for 4617 (median age 65 yr, both cohorts). Adjusted odds of high-grade prostate cancer were 1.77 times greater (95% confidence interval [CI] 1.57-2.00, p < 0.001, risk ratio [RR] = 1.40) with first-degree prostate cancer, 1.38 (95% CI 1.07-1.77, p = 0.011, RR = 1.22) for second-degree prostate cancer, and 1.30 (95% CI 1.01-1.67, p = 0.040, RR = 1.18) for first-degree breast cancer family histories. Interaction terms revealed that the effect of a family history did not differ based on prostate-specific antigen but differed based on age. This study is limited by missing data on race and prior negative biopsy.
conclusionsMen with indications for biopsy and a family history of prostate or breast cancer can be counseled that they have a moderately increased risk of high-grade prostate cancer, independent of other risk factors. PATIENT SUMMARY: In a large international series of men selected for prostate biopsy, finding a high-grade prostate cancer was more likely in men with a family history of prostate or breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.